Enzalutamide Approved for Nonmetastatic CSPC With Biochem...

What this episode covers

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.

Share this episode

Similar Episodes

Sacramento Crime Report — June 20, 2026

Jun 20, 2026 ·2m

Sacramento Crime Report — June 15, 2026

Jun 15, 2026 ·3m

Sacramento Crime Report — June 14, 2026

Jun 14, 2026 ·2m

Sacramento Crime Report — June 13, 2026

Jun 13, 2026 ·3m

Sacramento Crime Report — June 12, 2026

Jun 12, 2026 ·3m

Sacramento Crime Report — June 11, 2026

Jun 11, 2026 ·3m

Similar Podcasts

NEWMORROW SESSIONS - A PodCast Series on the Future of Hospitality Mario C. Bauer, Florian Schneider, Axel Weber & Dr. Tillman Bardt The Newmorrow PodCast is more than a podcast — it's a platform for open dialog on the future of our business, a platform for those building what doesn’t exist yet. Here, we share and embrace our passion for the hospitality industry, but we won’t romanticize the journey. We ask the tough questions, confront uncomfortable truths, and prepare for a future that resists easy answers. We believe that the tougher and wilder times become, the more openly, honestly and humanely people need to talk to each other and act together. We believe, openness, togetherness, and truthfulness should also be cornerstones of a professional community to develop our utopian idea of „open source“. This is a space where visionaries don’t just imagine the future — they wrestle with the paradoxes that shape it: success vs. happiness, data vs. instinct, stability vs. reinvention. Join leaders, entrepreneurs, and thinkers as they share not what made them — but what’s actively shaping them, now and next. So tune in The Health Odyssey: Navigating Tomorrow's Medicine Podcast Welcome to 'The Health Odyssey: Navigating Tomorrow's Medicine,' where we embark on an adventurous journey through the ever-evolving world of healthcare. Each episode is like a treasure map, guiding you through the rich tapestry of ancient healing arts mixed with futuristic tech wizardry. We’ll chat about the wild west of health data privacy, the corporate giants reshaping our care, and the mind-bending potential of psychedelics for mental wellness. Think of us as your trusty sidekicks, unraveling the mysteries of modern medicine while keeping it real and relatable. Let’s dive into the stories, the science, and the soul of healthcare, paving the way for a healthier tomorrow. The Syndicate Blogcast: Startups | Startup Investing | Tech News | Angel Investors | VC | Venture Capital | Private Equity | Crowdfunding | Fundraising Matt Ward - Serial Entrepreneur | Angel Investor | Startup Advisor | Amazon Ecommerce The Syndicate Blogcast show is an extension of The Syndicate podcast, featuring long form articles on the future technology, ecommerce, business and life. The mini-sodes deconstruct high level startup, business and tech issues to help investors and operators better understand and win the market. Recurring topics include: Facebook, Google, Amazon, Apple, Ecommerce, Blockchains, ICOs, Cryptocurrencies, Marketing, Fundraising, Venture Capital, Startup Challenges, Business Development and more. The Blogcast comes in addition to The Syndicate - the place where investors and startups combine to create crazy businesses and even crazier returns. The Syndicate podcast is a deep dive on the angel investors and VCs behind the big name startups. We interview the best and brightest investors, syndicate leads, GPs, limited partners and startup founders to create an original, off the cuff discussion on startup investing. Talent Stacker Jonathan Mendonsa Data suggests that the average cost of college in 2019 was $122,000 while the entry-level salary for a college graduate at the same time period was 50,000. ROI is a distant memory.hopefully for that that $122,000 the student graduates with a degree and possibly some skills. The reality is, as most individuals approach graduation, they realize that ultimately what they have to prove to their employers that they actually have the skills and since you don't need a degree or permission to start building skills, let’s document the stories and best practices of individuals that crushed the game by focusing on building their skills and their talent stack. Maybe you feel like you don’t have a talent stack. What are the skills you need to be able to generate an above-median income and when paired with interest-led learning this talent stack will allow you to work towards financial independence and design your future?If you're up for this challenge to go from no Talent Stack to designing you

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 13 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on December 5, 2023.

What is this episode about?

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology...

Can I download this Oncology Data Advisor episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.